OUR IMPACT ON ACCESS TO SEXUAL AND REPRODUCTIVE HEALTH MEDICINES AND TECHNOLOGIES

Concept Foundation has been facilitating access to sexual and reproductive health  (SRH) medicines and technologies in high need, low resource settings since 1989. Over the past three decades, our work has been transformational in the SRH field by expanding the method mix of modern contraceptive methods and essential maternal health medicines available to women in low- and middle-income countries that are safe, effective and affordable.

Photo Credit: Paul Joseph Brown Photography

OUR IMPACT ON ACCESS TO SEXUAL AND REPRODUCTIVE HEALTH MEDICINES AND TECHNOLOGIES

Concept Foundation has been facilitating access to sexual and reproductive health  (SRH) medicines and technologies in high need, low resource settings since 1989. Over the past three decades, our work has been transformational in the SRH field by expanding the method mix of modern contraceptive methods and essential maternal health medicines available to women in low- and middle-income countries that are safe, effective and affordable.

Photo Credit: Paul Joseph Brown Photography

key results:

Concept Foundation has led and contributed to achieving the following milestones in sexual and reproductive health

We are aligned with the UN Sustainable Development Goals (SDGs) target indicators on reducing maternal mortality, and ensuring universal access to sexual and reproductive healthcare services and rights for women and girls in low-and middle- income settings.

  •  The manufacture and introduction of the first once-a-month injectable contraceptive, Cyclofem®, in low- and middle-income country (LMIC) markets
  • Introduction of the first dedicated emergency contraceptive pill, Postinor-2, for LMIC markets
  • The development and launch of Medabon®, a dedicated co-packaged product for medical abortion and its registration in 27 countries
  • The conduct of several transformative studies on quality of hormonal contraceptives and maternal health products (see publications)
  • Over 30 quality-assured/WHO prequalified generic SRH medicines available for supply in LMIC markets
  • The development of safer and more cost-efficient manufacturing practices for SRH medicines

FOCUS ON 3 monthly INJECTABLE CONTRACEPTION

3-monthly injectable contraception (DMPA) is one of the most commonly used methods of contraception in sub-Saharan Africa. Until 2019, the only quality-assured product available for supply in some of the poorest countries of the world was the innovator product manufactured by Pfizer. CF has been working with manufacturers of generic DMPA since 2012 to address the barriers to making quality-assured injectable contraception more widely available.

Read more here.

STUDIES ON QUALITY OF ESSENTIAL MATERNAL HEALTH PRODUCTS

Postpartum haemorrhage (PPH) continues to affect women in LMIC due to a lack of effective and affordable treatment and is one of the leading causes of maternal mortality. Every day approximately 830 women die from preventable causes related to pregnancy and childbirth. 99% of all maternal deaths occur in LMIC settings and more in women living in rural and poverty-stricken settings. CF is working to reduce preventable maternal mortality by increasing access to quality-assured maternal health medicines and generating evidence of poor quality medicines is instrumental in this work.

Read more here.

REGISTRATION OF MEDABON® FOR SAFE MEDICAL ABORTION

Unsafe abortion compromises the lives and long-term health of women and girls, overwhelmingly in LMIC, where the majority of the 25 million unsafe abortions that occur each year take place. In 2007 Medabon®, a combination product for prevention of unsafe abortion, was launched by CF in partnership with the WHO and Sun Pharmaceuticals Ltd. (India). With CF’s support the product has been registered in 27 LMIC markets and CF continues to work on expanding market access to this essential product, with a current focus on Central Asia.

Read more here.

Our strategic approach to getting results:

Our vision is anchored in the belief that access, affordability and quality are the three basic requirements for any healthcare medicine or technology to be delivered safely and effectively. Access to high quality SRH medicines and technologies is core to achieving Universal Health Coverage. We believe that a holistic and systematic approach, based on an in depth understanding of the developmental, logistical and contextual challenges at the global, regional and national levels is essential to maximizing access to SRH medicines and technologies that are safe, effective and affordable. Our focus on SRH medicines and technologies spans the product development life-cycle from early research, to product development and manufacturing, regulatory approval and country level market access, and is the basis for our three strategic programme areas.